A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Summary

The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.

Timeline

Start

2025-10-10

Primary completion

2026-12-15

Completion

2028-08-15

Drugs

Indications